Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 2 )*

 

Sierra Oncology, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

82640U404

(CUSIP Number)

November 5, 2021

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐

Rule 13d-1(b)

 

☒

Rule 13d-1(c)

 

☐

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 82640U404
1	NAMES OF REPORTING PERSONS
	Vivo Capital IX, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☒
	(b)    ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		431,947 (1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		431,947 (1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	431,947 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.4% (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

 

(1)

The number represents (a) 324,783 shares of common stock, par value $0.001 per share (the “Common Stock”) of Sierra Oncology, Inc. (the “Issuer”) and (b) 107,164 shares of Common Stock issuable upon exercise of Series B warrants, the exercise of which is subject to a beneficial ownership limitation of 19.99% of the Issuer’s outstanding shares of Common Stock. The number excludes 324,740 shares of Common Stock issuable upon exercise of Series A warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding shares of Common Stock. The securities are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

 

(2)

Based on (a) 12,560,642 shares of Common Stock of the Issuer outstanding as of August 2, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2021, and (b) 107,164 shares of Common Stock issuable upon exercise of Series B warrants.

 

 

CUSIP No. 82640U404
1	NAMES OF REPORTING PERSONS
	Vivo Opportunity, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☒
	(b)    ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		1,935,853 (1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		1,935,853 (1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,935,853(1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	14.8% (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

 

(1)

The number represents (a) 1,455,576 shares of Common Stock and (b) 480,277 shares of Common Stock issuable upon exercise of Series B warrants, the exercise of which is subject to a beneficial ownership limitation of 19.99% of the Issuer’s outstanding shares of Common Stock. The number excludes 1,455,384 shares of Common Stock issuable upon exercise of Series A warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding shares of Common Stock. The securities are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.

 

(2)

Based on (a) 12,560,642 shares of Common Stock of the Issuer outstanding as of August 2, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2021, and (b) 480,277 shares of Common Stock issuable upon exercise of Series B warrants.

 

 

CUSIP No. 82640U404
1	NAMES OF REPORTING PERSONS
	Vivo Ventures VII, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☒
	(b)    ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		161,712 (1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		161,712 (1)
	8	SHARED DISPOSITIVE POWER

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	161,712(1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	1.3% (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

 

(1)

The number represents (a) 136,716 shares of Common Stock and (b) 24,996 shares of Common Stock issuable upon exercise of Series B warrants, the exercise of which is subject to a beneficial ownership limitation of 19.99% of the Issuer’s outstanding shares of Common Stock. The number excludes 75,749 shares of Common Stock issuable upon exercise of Series A warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding shares of Common Stock. The securities are held of record by Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P.

 

(2)

Based on (a) 12,560,642 shares of Common Stock of the Issuer outstanding as of August 2, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2021, and (b) 24,996 shares of Common Stock issuable upon exercise of Series B warrants.

 

 

Item 1.

(a)

Name of Issuer:

 

Sierra Oncology, Inc.

 

(b)

Address of Issuer’s Principal Executive Offices:

 

1820 Gateway Drive, Suite 110, San Mateo, CA, 94404

 

Item 2.

(a)

Name of Person Filing:

 

This Amendment No. 2 to Schedule 13G is filed jointly by Vivo Capital IX, LLC, Vivo Opportunity, LLC and Vivo Ventures VII, LLC.

 

(b)

Address of Principal Business Office or, if None, Residence:

 

192 Lytton Avenue, Palo Alto, CA 94301

 

(c)

Citizenship:

 

Vivo Capital IX, LLC is a Delaware limited liability company.

 

Vivo Opportunity, LLC is a Delaware limited liability company.

 

Vivo Ventures VII, LLC is a Delaware limited liability company.

 

(d)

Title of Class of Securities:

 

Common Stock, par value $0.001 per share

 

(e)

CUSIP Number:

 

82640U404

 

Item 3.

If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)

☐

Broker or dealer registered under Section 15 of the Act.

 

(b)

☐

Bank as defined in Section 3(a)(6) of the Act.

 

(c)

☐

Insurance company as defined in Section 3(a)(19) of the Act.

 

(d)

☐

Investment company registered under Section 8 of the Investment Company Act of 1940.

 

(e)

☐

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f)

☐

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g)

☐

A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

 

(h)

☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

(i)

☐

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

(j)

☐

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k)

☐

Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:

 

(1) Vivo Capital IX, LLC

 

The 324,783 shares of Common Stock and 107,164 shares of Common Stock issuable upon exercise of Series B warrants are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(2) Vivo Opportunity, LLC

 

The 1,455,576 shares of Common Stock and 480,277 shares of Common Stock issuable upon exercise of Series B warrants are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Hongbo Lu, Frank Kung, Michael Chang and Kevin Dai, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(3) Vivo Ventures VII, LLC

 

The 136,716 shares of Common Stock and 24,996 shares of Common Stock issuable upon exercise of Series B warrants are held of record by Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. The voting members of Vivo Ventures VII, LLC are Frank Kung, Edgar Engleman and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(b)

Percent of class:

 

Vivo Capital IX, LLC: 3.4%

 

Vivo Opportunity, LLC: 14.8%

 

Vivo Ventures VII, LLC: 1.3%

 

(c)

Number of shares as to which such person has:

 

(i)

Sole power to vote or to direct the vote:

 

Vivo Capital IX, LLC: 431,947 shares

 

Vivo Opportunity, LLC: 1,935,853 shares

 

Vivo Ventures VII, LLC: 161,712 shares

 

(ii)

Shared power to vote or to direct the vote: 0

 

(iii)

Sole power to dispose or to direct the disposition of:

 

Vivo Capital IX, LLC: 431,947 shares

 

Vivo Opportunity, LLC: 1,935,853 shares

 

Vivo Ventures VII, LLC: 161,712shares

 

(iv)

Shared power to dispose of or to direct the disposition of: 0

 

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

Not Applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.

Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	Vivo Capital IX, LLC
	November 5, 2021
	(Date)
	/s/ Frank Kung
	(Signature)
	Managing Member
	(Title)
	Vivo Opportunity, LLC
	November 5, 2021
	(Date)
	/s/ Gaurav Aggarwal
	(Signature)
	Managing Member
	(Title)
	Vivo Ventures VII, LLC
	November 5, 2021
	(Date)
	/s/ Frank Kung
	(Signature)
	Managing Member
	(Title)

 

 

8